Sentence examples for pharmaceutical resources from inspiring English sources

Pharmaceutical Resources did not disclose total net income and would report complete results April 29.

The bathroom cabinet contained an unfamiliar antibiotic, possibly bought in Eastern Europe, and not listed in any of the standard pharmaceutical resources.

PHARMACEUTICAL RESOURCES INC., Spring Valley, N.Y., a maker of a generic form of the antidepressant Prozac, said it had acquired FineTech Ltd., a pharmaceutical research unit, from International Specialty Products Inc., Wayne, N.J., for $32 million in cash.

Pharmaceutical Resources, the holding company for the generic-drug maker Par Pharmaceutical, said yesterday that first-quarter net income rose to 80 cents a share from 67 cents, less than analysts had expected.

Grasso and Genest found that medication error rates might be reduced by physician use of PDA pharmaceutical resources [ 12].

In the past two decades, microalgae have received increasing attention due to their great potential as an alternative resource in biofuel production and in other field applications, such as pharmaceutical resources, aquaculture feeds, and human food [ 1].

Medical and pharmaceutical resource use will be confirmed directly via Pharmaceutical Benefits Scheme PBSS) and Medicare Benefits Schedule (MBS) data.

Various reforms and interventions have been implemented to address shortages of pharmacists, such as the introduction of incentives, the impact of which is yet to be determined on pharmaceutical human resource trends [ 8] and new models of centralised dispensing of medicines for chronic conditions [ 9, 10].

One example is the research and development resources pharmaceutical companies frequently spend on developing drugs that are similar to others already available, rather than developing treatments for diseases for which there are no cures.

Compared to the pharmaceutical companies, our resources were small, but due to the strong local academic participation, we had been successful in recruiting capable gynaecologists and midwives and had only a small turnover of research personnel.

Limited pharmaceutical and financial resources, inadequate understanding of the role and nature of the CHA programme and communication challenges between various stakeholders contributed to competition between CHAs and existing staff.